Blood and clinical data collection to design a lung nodule biomarker panel
Official title: Specimens for Lung Cancer Panel Design
Run by Maverix Medical · NCT07401797 · Data updated 2026-11-12
This project will test blood biomarkers plus clinical information to see if they can better detect and confirm lung cancer in people with suspicious lung nodules before any invasive diagnosis or treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Maverix Medical Industry-sponsored |
| Locations | 1 site (Phoenix, Arizona) |
| Status | Recruiting |
| Started | August 7, 2024 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | February 10, 2026 |
| Trial ID | NCT07401797 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People with at least one indeterminate lung nodule ≥5 mm and a Mayo SPN risk >5%, who have not had prior cancer, have not yet undergone biopsy or surgery, can give 40 mL of blood, and have planned follow-up within the next seven months are ideal candidates.
✕Probably not a fit
Patients with very high-risk or large nodules (Mayo SPN risk >50% or diameter ≥30 mm), those with a prior cancer diagnosis, or those who have already begun surgical prep are excluded and unlikely to benefit from the biomarker findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study enrolls people with indeterminate lung nodules identified on imaging and collects peripheral venous blood (about 40 mL) and relevant clinical data before any biopsy or surgery. Eligible nodules must be ≥5 mm with a Mayo SPN risk >5% but not extremely high risk or very large nodules, and participants should have planned follow-up (biopsy, PET, or surveillance) within about seven months. Collected samples will undergo multiple laboratory analyses to find the optimal subset of biomarkers based on accuracy (sensitivity, specificity, improvement over other methods) and practical considerations like ease of collection and transport. Results are for research only, will not be shared with treating physicians, and will not change patient care.
Why it matters
Potential benefit: If successful, this could enable a blood-based test that helps detect and confirm lung cancer earlier and reduce unnecessary invasive procedures.
How similar studies have gone: Similar approaches using circulating tumor DNA and protein or multi-analyte biomarker panels have shown promise in early studies but have not yet produced a definitive, widely adopted blood test for early lung cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
6.1 Criteria for the no prior cancer suspicious nodule arm Inclusion: 1. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery. 2. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months. 3. Ability to understand the study and sign an informed consent form 4. Relevant clinical data accessible 5. Ability and willingness to safely donate 40 mL of blood 6. Ability of the site to collect and process blood per protocol Exclusion 1\. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater. 2\. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary. 3\. Previous cancer diagnosis of any origin. 4. Is currently pregnant 5. Is currently a prisoner or becomes a prisoner at any point during the study 6. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf 6.2 Criteria for the previous cancer suspicious nodule arm Inclusion: 1\. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery. 2\. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months. 3\. The patient has been in remission for a previous cancer not of lung origin for more than 5 years. 4\. Ability to understand the study and sign an informed consent form 5. Relevant clinical data accessible 6. Ability and willingness to safely donate 40 mL of blood 7. Ability of the site to collect and process blood per protocol Exclusion 1. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater. 2. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary. 3. Previous cancer diagnosis in the lung (either of lung origin or metastasis to the lung). 4. The treating physician believes the lung nodule is a recurrence of a previously diagnosed cancer. 5. Is currently pregnant 6. Is currently a prisoner or becomes a prisoner at any point during the study 7. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf 6.3 Criteria for the healthy volunteer arm Inclusion: 1. Ability to understand the study and sign an informed consent form 2. Relevant clinical data accessible 3. Ability and willingness to safely donate up to 40 mL of blood 4. The ability of the site to collect and process blood per protocol Exclusion 1\. Is currently pregnant 2. Is currently a prisoner or becomes a prisoner at any point during the study 3. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf
Where it's running
-
Maverix Medical
Phoenix, Arizona, United States Recruiting
Study contacts
- Principal investigator: Scott Morris, PhD — Maverix Medical
- Study coordinator: David Mallery
- Email: dmallery@maverixmedical.com
- Phone: 858-245-4239
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pre-Emptive Parecoxib for Pain During CT-Guided Lung Nodule Localization
This study tests whether giving parecoxib sodium before a CT-guided needle localization of lung nodules can reduce pain for patients undergoing VATS.
-
AI-driven autonomous registration for robotic bronchoscopy localization
This trial will test whether an AI system can automatically register and help guide robotic bronchoscopy for adults who need pulmonary nodule localization.
-
Shape-sensing robotic bronchoscopy to diagnose peripheral lung nodules
This tests a shape-sensing robotic bronchoscopy to see if it can get tissue samples from adults in Korea with peripheral lung nodules.
-
Robot-assisted dye marking for lung nodule surgery
This study tests if using a robot to help mark lung nodules before surgery works better than the usual method for people with lung nodules found on CT scans.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.